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An increased incidence of systemic cancers has been
described in some reports of familial atypical multiple
mole-melanoma kindreds. If the gene defect underlying
the familial atypical multiple mole-melanoma syndrome
is not only important for the development of melanoma
of the skin, the impact of the defect on life expectancy
may be much higher than previously thought. We
investigated all-cause mortality from 1830 to the present
and causes of death from 1941 to 1994 in proven,
obligate, and potential CDKN2 mutation carriers to
obtain an estimate of the impact of a hereditary defect
of the CDKN2 gene on mortality. From 1830 to 1994
there were 65 deaths, although only 42 deaths were
expected [standardized mortality ratio (SMR) 1.6, 95%
confidence interval (CI) 1.2-2.0] and the SMR doubled
with calendar time. Excess mortality was shown in
most of the families, but was confined to ages 35—70 y
(SMR 2.1, 95%CI 1.5-2.9). Excess mortality could be
fully attributed to cancer mortality, especially to
pancreatic carcinoma and melanoma of the skin. There
appeared to be some heterogeneity among the families,
especially due to the specific cancer pattern within a
family. The impact of the defect of the CDKN2 gene
is rising over calendar time, mainly because the
mortality in the general population has been falling.
Excess mortality was not only due to melanoma, but
also to pancreatic carcinoma. Therefore, follow-up
programs of affected family members should not be
confined to a regulär check of the atypical nevi. Key
words: causes of death/FAMMM/SMR. J Invest Dermatol
110:788-792, 1998
S
mce 1951 there has been mountmg evidence that up to
12% of cutaneous melanomas düster in families (Cawley,
1952, Greene et al, 1978, Greene and Fraumem, 1979,
Newton, 1994, Haluska and Housman, 1995) In many of
these families with a susceptibility to melanoma, the mdi-
viduals have an underlying syndrome of multiple atypical nevi (Greene
and Fraumem, 1979, Bergman et al, 1986, Newton, 1994) This
condition, the familial atypical multiple mole-melanoma (FAMMM)
syndrome (Lynch et al, 1978), is also known äs the B-K mole syndrome
(Clark et al, 1978), the dysplastic nevus syndrome (Eider et al, 1980),
or the atypical mole syndrome (Newton et al, 1993) The underlying
gene defect has an autosomal dominant inheritance pattern with
variable expression and mcomplete penetrance (Bergman et al, 1986),
but it seems plausible that more genes are mvolved (Newton, 1994)
The three known melanoma susceptibility loci are located on Ip36
(Bale et al, 1989), 12ql3 (Zuo et al, 1996), and 9p21 (Kamb et al,
1994) The latter legion contams a tumor suppressor gene, the CDKN2
gene, also known äs p!6INK4 The protem p!6 is a cell cycle regulator
and mhibits the kmase acüvity of CDK4/cyclm D (Serrano et al, 1993)
An increased incidence of systemic cancers has been described m
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some reports of FAMMM kindreds (Lynch et al, 1981, Bergman et al,
1990, Tucker et al, 1993), accordmg to others this can be attributed
to the method of ascertamment of the farmlies (Greene et al, 1987)
Neoplasms most often found m those families, besides melanoma of
the skin, are nonmelanoma skin cancer and cancers of the lung,
breast, stomach, pancreas, large bowel, and endometnum (Greene and
Fraumem, 1979) If the gene defect underlying the FAMMM syndrome
is not only important for the development of melanoma of the skin,
but also for a whole ränge of other hfe threatemng systemic neoplasms,
the impact of the defect on life expectancy may be much higher than
previously thought Knowledge of the natural history of the effects of
mutations in the CDKN2 gene may have consequences for follow-up
programs ot affected family members
Life expectancy m mdividuals with the FAMMM syndrome can
only be studied durmg long-term follow-up We developed a method
to study the survival of family members retrospectively by extendmg
the follow-up to the past (Rosendaal et al, 1991) In this study we
selected six FAMMM pedigrees and investigated all-cause mortality
from 1830 to the present and causes of death from 1941 to 1994 in
proven, obligate, and potential camers to obtain an estimate of the
impact of a hereditary defect of the CDKN2 gene on mortality and
causes of death
MATERIALS AND METHODS
Study population In February 1982 the Pigmented Lesions Climc of the
Department of Dermatology was estabhshed, facilitating studies on familial
melanoma From this database, 10 families were found with more than two
melanoma patients m at least two consecutive generations and in which several
family members showed atypical nevi These FAMMM fanuhes have been
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described in detail elsewhere (Bergman et al, 1986, 1990, 1992; Vasen et al,
1989). Six families, all showing an autosomal dominant pattern of inheritance
for a 19 bp deletion in exon 2 of the CDKN2 gene, were included in our
current invesrigation (Gruis et al, 1995). Two of the four remaining families
had the deletion but were not suitable for the mortality analysis because of an
unclear inheritance pattern of the CDKN2 gene, and two families originated
frorn a different part of the Netherlands and did not show the deletion.
We restricted the study population to proven camers of the deletion in
CDKN2, obligate, and potential gene carriers. Proven CDKN2 deletion carriers
had been confirmed by DNA analysis to carry the mutaöon (Gruis et al, 1995).
Obligate carriers were family members who had passed on the gene from
common ancestors to gene carriers amongst their ofßpring. Potential carriers
were defined äs all first degree relatives of gene carriers. Some of the potential
carriers could be tested for the deletion; however, the outcome on the DNA
test was only used to enlarge the pedigrees, meaning that all potential carriers
were part of the study population regardless of their DNA test. (Because only
Hving family members could undergo the test, excluding potential carriers after
the test would introduce bias towards deceased people.)
Using church and municipal registers of births, marriages, and deaths, we
retrieved the dates of birth and death for all individuals. Because the obligate
carriers had to live until the birth of the proven carrier to pass on the mutation,
the person-years lived before 20 y of age were ignored in these carriers. Besides,
because only a few melanoma occur before 20 y of age, the best estimate of
the gene impact on life expectancy can be made from this age on. Therefore,
follow-up extended from 20 y after the date of birth to the date of death or to
December 31, 1994.
Causes of death We were able to survey all causes of death of persons who
died in the Netherlands between 1941 and 1994. These were made available
by the Netherlands Central Bureau of Statistics, where one copy of each death
certificate is kept. The causes of death are routinely coded by this Bureau using
the coding rules from the International Classification of Diseases, fifth through
ninth revision (ICD-5 through ICD-9; WHO, 1940, 1948, 1957, 1968, 1977).
For the analysis, the older ICD codes were recoded to conform to the ninth
revision. We classified the deceased persons into malignant neoplasms (ICD-9
codes 140.0-209.9), diseases of the circulatory System (ICD-9 codes 390.0-
459.9), and remaining causes of death. Malignant neoplasms were further
Jivided into cancers of the digestive organs other than pancreas (ICD-9 codes
150.0-159.9, excluding 157), pancreatic carcinoma (ICD-9 codes 157.0-157.9),
nelanoma of the skin (ICD-9 codes 172.0-172.9), and remaining cancers. The
ompanson of causes of death was based on death certificate classifications to
;uarantee a valid comparison äs the classification was the same for both the
tudy and the control populations.
itatistical analysis Mortality data were analyzed with the Family Tree
-lortality Ratio method (Rosendaal et al, 1991; Hille et al, 1997): the overall
nd cause-specific mortality of the FAMMM families (observed) was compared
ath that of the general Dutch population adjusted for sex, age, and calendar
eriod (expected). The ratio of observed to expected number of deaths is the
andardized mortality ratio (SMR), which can be viewed äs a relative risk.
'he expected mortality was derived by multiplying the total number of years
ved by the study population per category of sex, age, and calendar period
•ith the corresponding cause-specific population mortality rates obtained from
le annual reports of the Netherlands Central Bureau of Statistics, using the
umputer program "Person-years" (Coleman et al, 1986). The 95% confidence
iterval (95%CI) for the SMR is based on a Poisson distribution for the
jserved number of deaths (Breslow and Day, 1987).
The calendar periods were divided into 20 y intervals from 1830 to 1889, a
ϊ y interval from 1890 to 1904, and 10 y intervals from 1905 to 1994. To
ch of these periods we applied the population mortality rates of the mid-
terval year, subdivided by sex and into 5 y age groups. For the causes of
•ath the calendar periods were assigned to 5 y intervals from 1941 to 1994,
bdivided by sex and into 5 y age classes. To each of these periods we applied
e cause-specific population mortality rates of the mid-mterval year, starting
>m the mid-interval year 1943 (period 1941—45) and running until 1993
eriod 1991-94).
Finally, to study differences among the families, we extended the SMR
alysis with Poisson regression analysis, using "EGRET" (EGRET, 1992).
lis multivariate analysis calculated rate ratlos for the different families adjusted
- sex, age, and calendar periods. We determined the differences between the
nilies for all-cause mortality and for mortality from malignant neoplasms from
41 to 1994. The pedigree that contributed most of the individuals and
rson-years to the analysis was taken äs the reference category.
RJESULTS
laracteristics of the study population Table I gives an overview
the characteristics of the study population for the six families. From
1830 to 1994, 224 family members, who were at least 20 y of age,
were followed over 6022 person-years. There were 87 proven, 23
obligate, and 114 potential CDKN2 gene carriers. Birth year ranged
from 1829 to 1974 and year of death from 1874 to 1994. The mean
age at the end-of-study date was 40.9 y (SD 15.4). For the entire study
population the mean age at death was 61.5 y (SD 16.7). In the 126
men the mean age at death was 59.1 y (SD 17.0), whereas the 98
women had a mean age at death of 65.3 y (SD 15.8).
All-cause mortality Over the whole period 65 'deaths occurred,
whereas only 42 deaths were expected (SMR 1.6, 95%CI 1.2-2.0). In
men, 40 individuals died in 3497 person-years, leading to a SMR of
1.5 (95%CI 1.1-2.0), and 25 women died in 2525 person-years (SMR
1.6, 95%CI 1.1—2.4). Excess mortality was shown in most of the
families, although there was some heterogeneity between the families
(Fig 1). The SMR doubled with calendar time, from 1870 to the
present (Fig 2). From the calendar period 1925-44 onward, the SMR
differed from unity, but the increase was only significant from 1975
onwards. Furthermore, Fig 3 shows that excess mortality was confmed
to the ages 35-70 y (SMR 42/19.7 = 2.1, 95%CI 1.5-2.9), with the
mortality peak between 40 and 50 (SMR 15/3.8 = 4.0, 95%CI 2.2-6.6).
Causes of death For the analysis of the causes of death between
1941 and 1994, 59 death certificates were reviewed. The all-cause
SMR over this period was slightly higher than for the whole period,
äs a result of a higher SMR in women (Table II). Excess mortality
can fully be attributed to malignancies, especially to melanoma of the
skin and pancreatic carcinoma, although half of the malignant neoplasms
resulted from several tumors, such äs lung, breast, and stomach cancers
(Table II). Separating the study population into proven and obligate
CDKN2 gene carriers versus potential carriers led to very similar
patterns in both groups, with, äs expected, the most pronounced risks
for those who were carriers with certainty (Table III). Because these
families have been ascertained on the basis of a history of melanoma,
there may be some bias in the melanoma mortality. The unbiased
result would be mortality other than melanoma of the skin. In these
families there were 49 deaths for reasons other than melanoma, leading
to a SMR of 1.4 (95%CI 1.1-1.9), and there were 34 deaths from
malignant neoplasms other than melanoma, with a SMR of 3.6 (95%CI
2.5-5.1).
Table IV shows all-cause mortality and deaths from malignant
neoplasms for the different families compared with the general Dutch
population (SMR) and compared with pedigree 10 (Poisson rate ratio;
the largest family). None of the differences between the families were
significant. Furthermore, it was striking that in two kindreds (FAMMM
l and 5) no one died from pancreatic cancer, and that in pedigree
number 5 no deaths from melanoma of the skin were mentioned on
the death certificates (Table IV).
DISCUSSION
We studied the mortality patterns in six FAMMM pedigrees. The all-
cause lifetime SMR for proven, obligate, and potential carriers with a
deletion in the CDKN2 gene was 1.6, with no significant differences
between men and women. Excess mortality started after the age of
30 y and could be fully attributed to cancer mortality. We found a
secular increase of mortality in the FAMMM families, mainly because
of decreasing mortality rates in the Dutch population over the past
Century. From the calendar period 1925—44 onward, the SMR differed
from unity, but the increase was only significant from 1975 onwards.
This means that the impact of the 19 bp deletion in exon 2 of the
CDKN2 gene is rising; in comparison with the general population it
becomes more disadvantageous to carry this gene.
All the FAMMM families were detected from the Pigmented Lesions
Clinic äs six separate families; however, when we found out that these
families all had the same 19 bp deletion in exon 2 of the CDKN2
gene, we started looking for common ancestors, especially because all
pedigrees came from the region of Leiden. From the finding of shared
haplotype among the melanoma patients, it had already been suggested
that there was a common mutation in the pedigrees (Bergman et al,
1994; Gruis et al, 1995). Genealogie investigation could confirm this
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1(n=25) 3(n=40) 4 (n=52) 5 (n=20) 10 (n=56) 19(n=31) All
Families
Figure 1. Excess mortality is present in most families. SMR with 95%CI,
per FAMMM family from 1850 all 1994, 3= 20 y of age.
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Calendar Periods
Figure 2. The SMR is rising over calendar titne. SMR with 95% CI, m
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Figure 3. Excess mortality is confined to age groups 40—70 y. SMR with
95%CI, m FAMMM families according to age groups from 1850 till 1994.
assumption: families l and 4 have common ancestors in 1775, and
together with kindred 3, they have a common ancestor in 1707.
Pedigrees 10 and 19 have common ancestors in 1763. We expect all
these FAMMM families to have one founder (far) before 1700. This
means that the differences between the families can be seen äs differences
between branches of one pedigree. As a consequence of new incoming
genes through spouses, differences between the different branches
develop.
There appears to be some heterogeneity among the families, especially
when taking into account the specific cancer pattern within a family.
In FAMMM families l and 5, there were no deaths from pancreatic
carcinomas and in kindred 5 no deaths from melanoma of the skin
were mentioned. This could be due to the small numbers studied.
Compared with family 10, all other kindreds had higher mortality
rates, though not significant. Families l and 4 were expected to be
more equal than the other families, because of the nearness of their
common ancestor. For the all-cause mortality and total cancer mortality
estimates this seemed to hold, although the specific cancer patterns in
these families differed.
Half of the cancer deaths were due to melanoma (10 deaths) and
pancreatic neoplasms (12 deaths). In addition, we also found an
increased mortality from digestive carcinomas other than pancreatic
(four deaths from stomach cancer), and from remaining cancers such
äs lung (five deaths) and breast (three deaths) cancers. All these types
of neoplasms had already been described in previous reports of FAMMM
kindreds, and relative risk estimates for melanoma and pancreatic
carcmoma were similar (Greene and Fraumeni, 1979; Lynch et al,
1981; Bergman et al, 1990; Tucker et al, 1993). These results confirm
the recent findings from Whelan et al (1995) that CDKN2 plays an
important role in both melanoma and pancreatic tumorgenesis. In the
same issue, Goldstein et al (1995) concluded that for the occurrence
of pancreatic cancer m FAMMM families, a mutation in the CDKN2
gene is required and that differences in cancer patterns between families
might be explamed by the kind of mutation; however, from the Dutch
families it has already been suggested that the differences in cancer
patterns cannot exclusively be explained by the kmd of CDKN2
mutation, but have to be mfluenced by other environmental or genetic
factors (Bergman and Gruis, 1996). The Impression that it is really the
CDKN2 gene that is causing the pancreatic carcmoma, is reinforced
äs the mortality risk was stronger in proven and obligate gene camers
than in potential gene camers. In both groups excess mortality could
be fully attributed to cancer mortality, especially to pancreatic carcinoma
and melanoma of the skin. Further evidence was given by the study
of Gruis et al (1995), where loss of heterozygosity of CDKN2 was
shown in pancreatic carcinoma tissue of one of the family members.
These FAMMM pedigrees have been ascertained on having more
than two melanoma patients in at least two consecutive generations
from the Pigmented Lesions Clinic. Therefore, the results could be
biased for deaths from melanoma. When omitting the melanoma
mortality, the excess mortality remained, meaning that deaths from
other cancers were äs important äs the melanoma mortality. This is
slightly different from the morbidity figures, where melanoma incidence
seems the most pronounced. Follow-up programs for the CDKN2
mutation carriers in these FAMMM kindreds, at this moment, consist
of a yearly check of the atypical nevi; however, on the basis of our
results the question is whether these gene carriers should not be
screened for cancers other than melanoma, especially for pancreatic
carcinoma. The problem is that currently no appropriate intervention
programs are available. From that perspective, it might be worthwhile
to study whether screening on serum tumor markers, like CAI 9-9 or
CA494 (Safi et al, 1986; Pleskow et al, 1989; Friess et al, 1993; Audisio
et al, 1996; Gansauge et al, 1996), in combination with regulär
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Table II. Observed and expected number of deaths for the difierent causcs of death between 1941 and 1994, 5t 20 γ of age


































































































































Observed number of deaths.
feExpected number of deaths.
Tour stomach, two biliary ducts, one coJon.
Five lung, three breast, two brain, one salivary gland, one nasopharynx, one prostate, one abdomen, one dissemmated.
Table III. Similar mortality pattern for potential carriers, though diluted, äs for proven and obligate carriers














































Table IV. AU-cause mortality and deaths from malignant neoplasms for the difFerent families compared with the general Dutch














































































~~*e a''umber of deaths.
ibserved n. ->ortality ratio with 95%CI in brackets.
andardized n· with the Jargest family (farmly 10) äs the reference group and 95%CI in brackets.
oisson rate ra ^ deaths fi-om digestive cancer, excluding pancreas.
-ibserved number o
ved number of ,)bserve '  r jg^ths from melanoma of skin.
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endoscopic viltrasonography or magnetic resonance imaging, for pancre-
atic carcinoma in CDKN2 mutation camers, rnight prevent rnore early
mortality in FAMMM families.
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